# Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)

> **NCT03594552** · NA · COMPLETED · sponsor: **King's College London** · enrollment: 87 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Arbaclofen_15
- **DRUG:** Arbaclofen_30
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03594552
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2020-03-12
- **Final completion:** 2020-03-12
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2022-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03594552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03594552, "Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03594552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*